XNCR
Xencor, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
28.00
▲ 1.00 (3.70%)
MARKET · —
Price
Open
26.62
Prev close
27.00
Day high
28.16
Day low
27.08
Volume
701.23K
Market cap
$2.07B
P/E (TTM)
—
52W range
7.71 – 28.16
Trailing performance
Returnvs SPY
1W
+19.11%
+20.5%
1M
+42.35%
+38.6%
3M
+146.67%
+143.6%
6M
+143.65%
+132.6%
YTD
+81.58%
+69.3%
1Y
+270.17%
+250.2%
3Y
+23.17%
-51.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.07B
Enterprise value$1.78B
Revenue (TTM)$104.97M
Gross profit$-150.79M
EBITDA$-205.90M
Net income$-163.32M
EPS (TTM)$-2.16
Free cash flow$-94.54M
Total cash$456.45M
Total debt$170.11M
Book value / share$8.84
Shares outstanding74.35M
Float54.25M
Short % of float21.64%
Dividend yield—
Beta (5Y)0.84
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.97
PEG ratio—
Price / sales—
Price / book3.14
EV / revenue16.96
EV / EBITDA-8.65
Gross margin-143.65%
Operating margin-72.37%
Profit margin-155.59%
Return on equity-29.07%
Return on assets-16.84%
Debt / equity33.80
Current ratio6.39
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $125.58M | $110.49M | $168.34M | $164.58M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$91.92M | -$232.62M | -$126.09M | -$55.18M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$91.92M | -$232.62M | -$126.09M | -$55.18M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.82 | -0.29 | +64.6% |
| Mar 2026 | -0.75 | -1.71 | -129.0% |
| Dec 2025 | -0.58 | -0.09 | +84.6% |
| Sep 2025 | -0.70 | -0.08 | +88.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.32 | 11 | $60.45M | +187.9% |
| Next quarter | -0.77 | 11 | $30.16M | +6.8% |
| Current year | -3.11 | 12 | $143.91M | +14.6% |
| Next year | -3.49 | 12 | $125.61M | -12.7% |
Analyst targets & ownership
Mean target$29.00
High target$44.00
Low target$14.00
Implied upside3.57%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy3 / 9
Hold2
Sell / Strong sell0 / 0
Held by insiders1.22%
Held by institutions114.77%
Institutions holding301
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+162.33K
Net buying
Buy transactions
12
242.75K shares
Sell transactions
13
80.42K shares
Net transactions
+25
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
907.11K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 18, 26 | FEIGAL ELLEN G. Director |
SELL | 6.84K | $89.37K | Direct |
| Jun 16, 26 | MONTGOMERY ALAN BRUCE Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | SIMPSON TODD E Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | RANIERI RICHARD J Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | GORMAN KEVIN CHARLES Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | GUSTAFSON KURT A Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | KLENCKE BARBARA M.D. Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | FEIGAL ELLEN G. Director |
STOCK | 10.30K | $0 | Direct |
| Jun 16, 26 | DESHAIES RAYMOND JOSEPH Director |
STOCK | 10.30K | $0 | Direct |
| Jun 15, 26 | MONTGOMERY ALAN BRUCE Director |
SELL | 5.06K | $62.34K | Direct |
| Jun 15, 26 | RANIERI RICHARD J Director |
SELL | 5.47K | $67.39K | Direct |
| Jun 15, 26 | GORMAN KEVIN CHARLES Director |
SELL | 7.53K | $92.66K | Direct |
| Jun 15, 26 | GUSTAFSON KURT A Director |
SELL | 5.47K | $67.39K | Direct |
| Apr 10, 26 | CORNELISSEN BART JAN Chief Financial Officer |
SELL | 3.50K | $42.99K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CORNELISSEN BART JAN |
Chief Financial Officer | 75.90K | Sale |
DAHIYAT BASSIL ISHMAEL |
Chief Executive Officer | 546.32K | Sale |
DESJARLAIS JOHN R |
Officer | 263.83K | Sale |
ECKERT CELIA E |
General Counsel | 76.92K | Sale |
GUSTAFSON KURT A |
Director | 25.01K | Stock Award(Grant) |
KLENCKE BARBARA M.D. |
Director | 29.97K | Stock Award(Grant) |
MONTGOMERY ALAN BRUCE |
Director | 25.85K | Stock Award(Grant) |
RANIERI RICHARD J |
Director | 24.01K | Stock Award(Grant) |
SIMPSON TODD E |
Director | 23.99K | Stock Award(Grant) |
VALENTE NANCY |
Officer | 49.17K | Sale |
Moving averages & technicals
SMA 10
24.40
+14.74% from price
SMA 20
22.25
+24.92% from price
SMA 50
18.16
+53.12% from price
SMA 100
15.16
+84.71% from price
SMA 200
14.47
+92.07% from price
EMA 12
24.32
+15.15% from price
EMA 26
21.83
+28.24% from price
EMA 50
19.26
+45.40% from price
RSI (14)
80.2
Overbought
MACD (12,26,9)
2.48
Hist 0.49
ATR (14)
1.34
4.83% of price
Realised vol 30D
77.1%
Annualised
Bollinger upper
27.63
20, 2σ
Bollinger lower
16.88
20, 2σ
50 / 200 cross
Golden
18.16 vs 14.47
Trend bias
Above 200
+92.07%
Risk profile
Beta vs SPY
1.28
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
77.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-42.6%
Peak to trough
Max drawdown 5Y
-83.9%
Peak to trough
ATR 14
1.34
4.83% of price
Beta (reported)
0.84
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.08
Call-heavy session
Put / call open interest
0.07
Positioning, not flow
Max pain
15.00
-46.0% from spot
ATM implied vol
60.4%
Nearest strike to spot
Skew (10% OTM)
+20.0%
Puts bid over calls
Call volume
26
Contracts, this expiry
Put volume
2
Contracts, this expiry
Heaviest call OI
20.00
35 contracts
Heaviest put OI
20.00
2 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit
Simply Wall St. · 14d ago
Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating
MT Newswires · 16d ago
RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating
MT Newswires · 16d ago
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 17d ago
Xencor: Q2 Earnings Snapshot
Associated Press · 17d ago
Xencor Reports Second Quarter 2026 Financial Results
Business Wire · 17d ago
Sector Update: Healthcare Stocks Decline Late Afternoon
MT Newswires · 23d ago
Sector Update: Healthcare
MT Newswires · 23d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.